Alembic Pharmaceuticals Ltd. Remains a Top Player in Pharma Industry Despite Recent Stock Dip
Alembic Pharmaceuticals Ltd. (Alembic) is a leading pharmaceutical company in the largecap industry. Despite a recent dip in stock performance, the company has a strong track record and has been given a 'Buy' call by MarketsMojo. While it has underperformed the sector and Sensex in the short term, its moving averages and long-term potential remain positive.
Alembic Pharmaceuticals Ltd. (Alembic) is a leading pharmaceutical company in the largecap industry. Despite a recent dip in stock performance, the company has a strong track record of success and continues to be a top player in the pharma market.
On August 29, 2024, Alembic Pharmaceuticals Ltd. saw a decrease of -3.27% in its stock price. However, this dip should not overshadow the company's overall performance and potential.
According to MarketsMOJO, a leading stock analysis platform, Alembic Pharmaceuticals Ltd. has been given a 'Buy' call. This is a testament to the company's strong fundamentals and potential for growth.
In terms of price performance, Alembic Pharmaceuticals Ltd. has underperformed the sector by -2.7% on the day of August 29, 2024. However, it is important to note that the stock has been on a consecutive fall for the last 5 days, with a -7.86% decrease in returns during this period. This could be a result of market fluctuations and should not be a cause for concern for long-term investors.
On the day of August 29, 2024, Alembic Pharmaceuticals Ltd. touched an intraday low of Rs 1025.05, representing a -3.27% decrease from its previous closing price. However, the stock's moving averages are still higher than the 100-day and 200-day moving averages, indicating a positive trend in the long run.
In comparison to the Sensex performance, Alembic Pharmaceuticals Ltd. has underperformed by -2.60% in the past day and -16.57% in the past month. However, it is important to note that the Sensex has also seen a decrease of 0.23% and 0.76% in the same time periods, respectively.
Overall, Alembic Pharmaceuticals Ltd. remains a strong player in the pharma industry with a solid track record and potential for growth. Investors should not be discouraged by the recent dip in stock performance, as the company continues to be a top performer in the largecap sector.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
